Sign In
Buy IKT
$2.18
-0.1000 (-4.39%)
At Close: Jul 31, 2026
Best Momentum Stocks to Buy for January 31st
11:01am, Wednesday, 31'st Jan 2024
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
New Strong Buy Stocks for January 31st
07:05am, Wednesday, 31'st Jan 2024
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
09:05am, Monday, 29'th Jan 2024
BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Best Momentum Stocks to Buy for January 26th
11:01am, Friday, 26'th Jan 2024
PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.
New Strong Buy Stocks for January 26th
07:26am, Friday, 26'th Jan 2024
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 22'nd Jan 2024
Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
05:38pm, Wednesday, 15'th Nov 2023
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Cal
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
09:28am, Tuesday, 07'th Nov 2023
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" r
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
08:05am, Tuesday, 22'nd Aug 2023
BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
08:05am, Monday, 07'th Aug 2023
BOSTON and ATLANTA , Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
08:05am, Tuesday, 30'th May 2023
BOSTON and ATLANTA , May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
08:05am, Monday, 08'th May 2023
BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor th
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
08:05am, Thursday, 04'th May 2023
BOSTON and ATLANTA , May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
08:30am, Friday, 21'st Apr 2023
BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
05:15pm, Thursday, 23'rd Mar 2023
BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibito
